Erythropoietin: Biochemical profile, biological records, indications and therapeutic results in hematology;Eritropoietina: Profilo biochimico, ricordi biologici, indicazioni e risultati terapeutici in ematologia

Tumori

Volumn 83, Issue 4 SUPPL. 2, 1997, Pages

  Marmont, Alberto M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

erythropoietin; hematologic diseases

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DRUG EFFICACY; ERYTHROPOIESIS; HEMATOLOGIC DISEASE; HEMATOLOGY; HEMOGLOBINURIA; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASIA; SURVIVAL;

ANIMALS; ERYTHROPOIETIN; HEMATOLOGIC DISEASES; HUMANS; RECOMBINANT PROTEINS;

EID: 0030813235     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (146)

1. Adamson J.W., Fialkow P.J., Murphy S., Perchal J.F., Steimann L.: Polycythemia vera: stem cell and probable clonal origin of the disease. N. Engl. J. Med., 295: 913-916, 1976.
2. Al-Khatti A., Veith R.W., Papayannopoulou T, Fritsch E.F., Goldwasser E., Stamatoyannopoulos G.: Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N. Engl. J. Med., 317: 415, 1987.
3. Al-Khatti A., Umemura T., Clow J., Abels R.I., Vance J., Papayannopoulou T., Stamatoyannopoulos G.: Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Trans. Assoc. Am. Physicians, 101: 54-71, 1988.
4. Aloe Spiriti M.A., Petti M.C., Latagliata R., Avvisati G., De Gregoris C., Proia S., Fazi P., Jaalouk G., Mancini M., Spadea A., et al.: Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwile? Leuk. Lymphoma, 9: 79-83, 1993.
5. Alter B.P.: Biology of erythropoiesis. Ann. NY Acad. Sci., 718: 165-176, 1994.
6. Aoki I., Nishijima R., Homori M., Nakahara K., Higashi K., Ishikawa K.: Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Epo) in vitro in multiple myeloma. Br. J. Haematol., 81: 463-469, 1992.
7. Asano H., Ohashi H., Ichihara M.: Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood, 84: 588-594, 1994.
8. Astori C., Bonfichi M., Pagnucco G., Bernasconi P., Lazzarino M., Orlando E., Bernasconi C.: Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. Br. J. Haematol., 97: 586-588, 1997.
9. Athens J.W., Lee G.E., Polycythemia: erythrocytosis In: Wintrobe's clinical hematology, Lee G.R., Bithel T.C., Foerster J., Athens J.W., Lukens J.N., Eds. Lea & Febiger, Philadelphia-London, p. 1245, 1993.
10. Bachmann S., Le Hir M., Eckardt K.U.: Co-localization of erythropoietin mRNA and ecto-5-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J. Histochem. Cytochem., 41: 335-317, 1993.
11. Bacigalupo A., van Lint M.T., Occhini D. et al: Recombinant human erythropoietin in the treatment of anaemia in patients undergoing allogeneic bone marrow transplantation. Erythropoiesis, 4: 80-84, 1993.
12. Balleari E., Gatti A.M., Mareni C., Massa G., Marmont A.M., Ghio R.: Recombinant human erythropoietin for long-term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Haematologica, 81: 143-147, 1996.
13. Balleari E., Mareni C., Marmont A.M., Ghio R.: Therapy with recombinant erythropoietin in paroxysmal nocturnal hemoglobinuria. Br. J. Haematol., 94: 424 (letter), 1996.
14. Bär B., Van Dijk B.A., Schattenberg A., de Man A., Kumst V., de Witte T.: Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant., 16: 793-799, 1995.
15. Barlogie B.: Treatment of the anemia of multiple myeloma: the role of recombinant erythropoietin. Sem. Hematol. 30: 25-27, 1993.
16. Barosi G., Cazzola M., De Vincentiis A., Grossi A., Tura S.: Guidelines for the use of recombinant human erythropoietin. Haematologica, 79: 526-533, 1994.
17. Bauer C.H.: Erythropoietin: from gene structure to therapeutic application. J. Perinat. Med., 23: 77-79, 1995.
18. Bauer C.H.: The oxygen sensor that controls EPO production: facts and fancies. J. Perinat. Med., 23: 7-12, 1995.
19. Bazan J.F.: Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA, 87: 6934, 1990.
20. Beguin Y., Clemens G.K., Oris R., Fillet G.: Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood, 77: 868-873, 1991.
21. Beguin Y.: Erythropoiesis and erythropoietin in multiple myeloma. Leuk. Lymphoma, 18: 413-421, 1995.
22. Bennett J.M., Catowsky D., Daniel M.T., Flandrin C., Galton D.A., Gralnick H.R., Sultan C.: Proposal for the classification of the myeloblastic syndromes. Br. J. Haematol., 51: 189-199, 1982.
23. Bierman P.J., Warkentin P., Hutchins M., Klassen L.: Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk. Lymphoma, 9: 169-171, 1990.
24. Blacklock H.A., Katz P., Michalevicz R., Hazlehurst G.R., Davies L., Prentice H.G., Hoffbrand A.V.: A and B blood group antigen expression on mixed colony cell and erythroid precursors. Relevance for human allogeneic bone marrow transplantation. Br. J. Haematol., 98: 267-276, 1984.
25. Bondurant M.C., Koury M.J., Koury S.T., Semenza G.: Erythropoietin ontogeny and organ distribution in mice. Sem. Hematol., 28: 20, 1991.
26. Bosi A., Vannucchi A.M., Grossi A., Guidi A.? Saccardi R., Rafanelli D., Longo G., Ferrini P.R.: Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica, 76: 280-284, 1991.
27. Bourantas K.: High-dose recombinant human erythropoietin and low-dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematol., 91: 62-65, 1994.
28. Casadevall N., Duphy E., Molho-Sabatier P., Tobelem G., Varet B., Mayeux P.: Brief report: autoantibodies against erythropoietin in a patient with pure red cell aplasia. N. Engl. J. Med., 334: 630-633, 1996.
29. Cazzola M., Beguin Y.: New tools for clinical evaluation of erythron function in man. Br. J. Haematol., 80: 278-286, 1992.
30. Cazzola M., Ponchio L., Beguin Y, Rosti V., Bergamaschi G., Liberato N.L., Fregoni U., Nalli G., Barosi G., Ascari E.: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood, 79: 29-37, 1992.
31. Clemens S., Spivak J.L.: Serum immunoreactive erythropoietin during the perioperative period. Surgery, 115: 510-515, 1994.
32. D'Andrea A.D., Fasman G.D., Lodish HF: Erythropoietin receptor and interleukin-2receptor beta chain. A new receptor superfamily. Cell, 58: 1023, 1989.
33. Dainak N., Huffman R., Lebowitz A.J., Solomon L., Maffei L., Ritchey K.: Erythropoietin-dependent primary pure erythrocytosis. Blood, 53: 1076-1084, 1979.
34. Damasio E.: L'uso dell'eritropoietina per la correzione del1'anemia nelle emopatie maligne. In: Nuove applicazioni in tema di fisiopatologia e terapia dell'anemia, pp. 42-45, Wichtig, Milano,1993.
35. Damen J.E., Krystal G.: Early events in erythopoietin - induced signaling. Exp. Hematol., 24: 1455-1459, 1996.
36. Dessypris E.N., Krantz S.B.: Effect of pure erythropoietin on DNA synthesis by human marrow day 15 erythroid burst forming units in short term culture. Br. J. Hematol., 56: 295, 1984.
37. Distelnorst C.W., Wagner D.S., Goldwasser E., Adamson J.W.: Autosomal dominant familial erythrocytosis due to autonomous erythropoietin production. Blood, 58: 1155-1160, 1981.
38. Eckardt K.U., Pugh C.W., Meier M., Tan C.C., Ratcliffe P.J., Kurtz A.: Production of erythropoietin by liver cells in vivo and in vitro. Ann. NY Acad. Sci., 718: 50-60, 1994.
39. Emerson S.G., Sieff C.A., Wang E.A., Wong G.G., Clark S.C., Nathan D.G.: Purification of fetal hematopoietic progenitors and characterization of recombinant multipotential colony-stimulating activity. J. Clin. Invest., 76: 1286-1290, 1985.
40. Emerson A.J., Westwood N.B., Rackham R.A., Stern C.M., Pearson T.C.: Erythropoietin responsive progenitors in anaemia of prematurity. Arch. Dis. Child, 66: 810-811, 1991.
41. Eridani S., Dudley J.M., Sawyer B.M., Pearson T.C.: Erythropoietic colonies in a serum-free system. Results in primary proliferative polycythemia and thrombocythemia. Br. J. Haematol., 67: 387-391, 1987.
42. Erslev A.J., Caro J., Besarah A.: Why the kidney? Nephron, 41: 213-216, 1985.
43. Fried W.: Erythropoietin. Ann. Res. Nutr., 25: 353-377, 1995.
44. Gallagher A., Darley R., Padua R.A.: The molecular basis of myelodysplastic syndromes. Haematologica, 82: 191-204, 1997
45. Glas J., Lavidor J.M., Robinson S.H.: Use of cell separator and short-term culture techniques to study erythroid cell development. Blood, 46: 105, 1975.
46. Glaspy J.A., Chap L.: The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol./Oncol. Clin. North Amer., 8: 945-959, 1994.
47. Goldberg M.A., Schneider T.J.: Similarities between the oxygen sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem., 269: 4355-4359, 1994.
48. Goldberg M.E.: Biology of erythropoietin. In: Erythropoietin in clinical applications, Garnick M.B., Ed., Dekker, New York & Basel, p. 59, 1990.
49. Goodnough L.T., Monk T.G., Andriole G.L.: Erythropoietin therapy. N. Engl. J. Med., 336: 933-938, 1997.
50. Greenberg P., Cox C., Le Bean M., Fenaux P., Morel P., Sanz G., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mugti G., Bennet J.: Controversies in the classification of myelodysplastic syndromes. Bone Marrow Transplant., 19 (suppl 1): S210 (abstr), 1997.
51. Griscelli Bennaceur A., Gluckman E., Scrobohaci M.L., Jonveaux P., Vu T, Bazarbachi A., Carosella E.D., Sigaux F., Socie G.: Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood, 85: 1354-1363, 1995.
52. Hagiwara M., Chen I.-L., McGonigle R., Beckman B., Kasten F.H., Fisher H.W.: Erythropoietin production in a primary culture of human renal carcinoma cells maintained in nude mice. Blood, 63: 828-835, 1984.
53. Hellstrom-Lindberg E., Birgerard G., Carlsson M., Carneskog J., Dahl I.M., Dyhedal I., Grimfors G., Merk K., Tangen J.M., Winquist I., et al.: A combination of G-CSF and erythropoietin may synergistically improve the anemia in patients with MDS. Leuk. Lymphoma, 11: 221-228, 1993.
54. Hellstrom-Lindberg E.: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol., 89: 67-71, 1995.
55. Henry D.H., Beall G.N., Benson C.A., Carey J., Cone L.A., Eron L.J., Fiala M., Fischl M.A., Gabin S.J., Gottlieb M.S., et al.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann. Intern. Med., 117: 739-748, 1992.
56. Henry D.H.: Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol./Oncol. Clin. North Amer., 8: 961-973, 1994.
57. Heyll A., Aul C., Runde V., Arning M., Schneider W., Wernet G.: Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin. Blood, 77: 906, 1991.
58. Huffman R., Zanjani E.D., Vila J., Zalusky R., Lutton J.D., Wasserman L.R.: Diamond-blackfan syndrome: lymphocyte-mediated suppression of erythropoiesis. Science, 193: 899-900, 1976.
59. Iscove N.N.: The role of erythropoietin in regulation of population size and cell cycling of early and late erythroid precursors in mouse bone marrow. Cell Tissue Kinet., 10: 323, 1977.
60. Jepson J.H., Lowenstein L.: Panhypoplasia of the bone marrow. I Demonstration of a plasma factor with anti-erythropoietin-like activity. Can. Med. Ass. J., 99: 99-101, 1968.
61. Karki K.K., Anderson L.C., Vuopio E., Gahmberg C.G.: Expression of blood group A antigens in human bone marrow cells. Blood, 57: 147-151, 1981.
62. Kaushansky K., Lin N., Grossmann A. et al: Thrombopoietin. Biologic expectations, physiologic surprises, and clinical promise. In: Abraham N., Asano S., Brittinger G., Maestroni G.L., Shadduck R.K. (Eds.): Molecular biology of hematopoiesis. Plenum, New York & London, 1996, pp. 477-483.
63. Kazal L.A., Erslev A.J.: Erythropoietin production in renal tumors. Ann. Clin. Lab. Sci., 5: 98, 1975.
64. Klaesson S., Ringden O., Ljungman P, Lonnquist B., Wennberg L.: Reduced blood transfusions requirements after bone marrow transplantation: results of a randomized, double-blind study with high-dose erythropoietin. Bone Marrow Transplant., 13: 397-402, 1994.
65. Klumpp T.R: Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant., 8: 159-170, 1991.
66. Koury MJ., Boundurant M.C.: The molecular mechanism of erythropoietin action. Eur. J. Biochem., 216: 649-655, 1992.
67. Koury M.J.: Programmed cell death (apoptosis) in hematopoiesis. Exp. Hematol., 20: 391, 1992.
68. Koury S.T., Bondurant M.C., Koury M.J.: Localization of erythropoietin sytnthetizing cells in murine kydneys by in situ hybridization. Blood, 71: 524, 1988.
69. Labar B., Bogdanic V, Nemet D., Kovacevic-Metelko J., Mrsic M., Pauletic Z., Zupancic-Salek S., Radman I., Aurer I.: Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. Bone Marrow Transplant., 10: 471-472, 1992.
70. Lacombe C., Bruneval P., De Silva J.L., Casadevall N., Camilleri J.P., Bariety J., Tambourin P., Varet B.: Production of erythropoietin in the kidney. Sem. Hematol., 28 (Suppl. 3): 14, 1991.
71. Lacombe C., De Silva J.L., Bruneval P.: Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest., 81: 620, 1988.
72. Legare R.D., Gilliland R.D.: Myelodysplastic syndromes. Curr. Opin. Hematol., 2: 283-292, 1995.
73. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U.: Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med., 322: 1693-1699, 1990.
74. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., Schuster J.: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood, 84: 1056-1063, 1994.
75. Marmont A.M., Frassoni F., van Lint M.T. et al: Isohemagglutinin-induced pure red cell aplasia following major ABO incompatible marrow transplant for severe aplastic anemia. Resolution after plasma exchange. Exp. Hematol., 11 (Suppl 13): 51-53, 1983.
76. Marmont A.M.: Eritropoietina: biologia ed indicazioni negli stati anemici non-renali. In: Nuove acquisizioni in tema di fisiopatologia e terapia dell'anemia, pp. 1-21, Wichtig, Milano, 1993.
77. Marmont A.M.: Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia. Leukemia, 6 (Suppl 4):167-171, 1992.
78. Marmont A.M.: Selective metaphasic blockade of erythroblasts in the bone marrow of patients treated with recombinant human erythropoietin and vincristine. Haematologica, 76: 251, 1991.
79. Marmont A.M.: Therapy of pure red cell aplasia. Sem. Hematol., 28: 285-297, 1991.
80. Martelli M., Ponchio L., Beguin Y., Meloni G., Mandelli F., Cazzola M.: Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica, 79: 456-459, 1994.
81. McMullin M.F., Hillmen P., Elder G.E., Lappin T.R., Luzzato L.: Serum erythropoietin levels in paroxysmal nocturnal hemoglobinuria: implications for therapy. Br. J. Haematol., 92: 815-817, 1996.
82. Means R.T.: Clinical application of recombinant erythropoietin in the anemia of chronic disease. Hematol./Oncol. Clin. North Amer., 8: 933-944, 1994.
83. Mercuriali F., Inghilleri G.: Eritropoietina umana ricombinante (r-HuEPO). Biologia e clinica. Milano, Adis, 1996.
84. Miller C.B., Mills S.: Erythropoietin after bone marrow transplantation. Hematol./Oncol. Clin. North Amer., 8: 975-992, 1994.
85. Misit J., Spivak J.L.: Separation of erythroid progenitor cells in mouse bone marrow by isokinetic-gradient sedimentation. Blood, 54: 105, 1979.
86. Mittleman M., Lessin L.S.: Clinical application of recombinant erythropoietin in myelodysplasia. Hematol./Oncol. Clin. North Amer., 8: 993-1009, 1994.
87. Mittleman M.: Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers. Acta Haematol., 90: 53-57, 1993.
88. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Penaux P.: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7: 1315-1323, 1993.
89. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin I.J., Machin D.: Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol., 59: 425-433, 1985.
90. Negrin R.S., Stein R.S., Doherty K., Cromwell J., Vardiman J., Krantz S., Greenberg P.: G-CSF plus erythropoietin for the maintenance treatment of the anemia of myelodysplastic syndromes. Blood, 87: 4076-4081, 1996.
91. Negrin R.S., Stein R., Vardiman J., Doherty K., Cornwell J., Krantz S., Greenberg P.L.: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82: 737-742, 1993.
92. Negrin R.S., Stein R., Vardiman R., Doherty J., Cornwell J. Krantz S., Greenberg P.L.: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82: 737-743, 1993.
93. Niemeyer C.M., Baumgarten E., Holldack J., Meier I., Trenn G., Jobke A., Eckhardt K.U., Reiter A., Sauter S., Riehm H.: Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib. Nephrol., 88: 276-280, 1991.
94. Nijhof W., Goris H., Dontje B., Dresz J., Loeffler M.: Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment. Exp. Hematol., 21: 496-501, 1993.
95. Nijhof W., Wierenga P.K., Sahr R., Beru N., Goldwasser E.: Induction of globin mRNA transcription by erythropoietin in differentiating erithroid precursors cells. Exp. Hematol., 15: 779-784, 1987.
96. Nomura S., Ogami K., Kawamura K., Beru N.: Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp. Hematol., 25: 638-648, 1997.
97. Obladen M., for the European Multicentre Erythropoietin Study: The effect of erythropoietin beta (recombinant human erythropoietin) on the need for tranfusion in very-low-birth weight infants. N. Engl. J. Med., 330: 1173-1178, 1994.
98. Obladen M., Maier R., Segerer H., Grauel E.L., Holland B.M., Stewart G., Jorch G., Rabe H., Linderkamp O., Hoffmann H.G., Houghton F., Herrmann Z., Scigalla P., Wardrop C.: Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European Randomized Multicentre Trial. Contrib. Nephrol., 88: 314-326, 1991.
99. Ogawa M., MacEachern M.D., Avila L.: Human marrow erythropoiesis in culture: heterogeneity in the morphology, time course of colony formation, and sedimentation velocities of the colony-forming cells. Am. J. Hematol., 3: 29, 1977.
100. Ohashi H., HottaT., Ichikawa A., Kinoshita T., Taguchi R., Kiguchi T., Ikezawa H., Saito H.: Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylnositol anchor proteins. Blood, 83: 853-859, 1994.
101. Or R., Naparstek E., Mani N., Slavin S.: Treatment for pure red cell aplasia following major ABO-mismatched T cell depleted bone marrow transplant. Transplant Int., 4: 99-102, 1991.
102. Orbach H., Ben-Yehuda A., Ben Yehuda D., Manor D., Rubinow A., Naparstek Y: Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin. J. Rheumatol., 22: 2166-2169, 1995.
103. Paltiel O., Cournoyer D., Rybka W.: Pure red cell aplasia following ABO-incompatible marrow transplantation: response to erythropoietin. Transfusion, 33: 418-421, 1993.
104. Papayannopoulou T., Finch C.A.: On the vivo action of erythropoietin: a quantitative analysis. J. Clin. Invest., 51: 1179, 1972.
105. Peschle C., Marmont A.M., Marone G., Genovese A., Sasso G.F., Condorelli M.: Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br. J. Haematol., 30: 411-417, 1975.
106. Rademacher T.W., Parekh R.B., Dwek R.A.: Glycobiology. Ann. Rev. Biochem., 57: 785-838, 1988.
107. Ried C.D. Annotation. In vitro studies of normal and pathological erythropoiesis. Br. J. Hematol., 82: 483, 1992.
108. Romanowski R.R., Sytkowsky A.J.: The molecular structure of human erythropoietin. Hematol./Oncol. Clin. North Amer., 8: 885-894, 1994.
109. Rose E.H., Abels R.I., Nelson R.A., McCullough D.M., Lessin L.: The use of r-HuEpo in the treatment of anemia related to myelodysplasia. Br. J. Haematol., 89: 831-837, 1995.
110. Rossi Ferrini P.L., Vannucchi A.M.: Terapia con eritropoietina dopo trapianto di midollo osseo. Prog. Ematol. Clin., 13: 115-121, 1994.
111. Runde V, Aul C., Ebert A., Grabenhorst U., Schneider W.: Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur. J. Haematol., 54: 39-45, 1995.
112. Santamaria A., Sureda A., Martino R. et al: Successful treatment with erythropoietin of pure red cell aplasia after major ABO-incompatible T cell depleted bone marrow transplantation. Bone Marrow Transplant., in press.
113. Sanz G.F., Sanz M.A.: Prognostic factors in myelodysplastic syndromes. Leukemia Res., 16: 77-86, 1992.
114. Sasaki H., Bohner B., Fukuda M.: Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem., 262: 12059-12076, 1987.
115. Sawyer S.T., Penta K.: Erythropoietin cell biology. Hematol./Oncol. Clin. North Amer., 8: 899-911, 1994.
116. Schrezenmeier H., Hertenstein B., Wagner B., Raghavachar A., Heimpel H.: A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp. Hematol., 23: 81-87, 1995.
117. Schuster S.J., Koury S.T., Bohrer M., Salceda S., Caro J.: Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br. J. Haematol., 81: 153-159, 1992.
118. Semenza G.L., Nejfelt M.K., Chi S.M., Antonarakis S.E.: Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 88: 5680-5686, 1991.
119. Semenza G.L.: Regulation of erythropoietin production. Hematol./Oncol. Clin. North Amer., 8: 863-884, 1994.
120. Shannon K.M., Keith J.F. III, Mentzer W.C., Ehrenkranz R.A., Brown M.S., Widness J.A., Gleason C.A., Bifano E.M., Milland D.D., Davis C.B., et al.: Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics, 95: 1-8, 1995.
121. Shannon K.M., Mentzer W.C., Abels R.I. et al: Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. Pediatr. Pharmacol. Therap., 118: 949, 1991.
122. Shannon K.M.: Recombinant erythropoietin in pediatrics: a clinical perspective. Pediatr. Ann., 19: 197, 1990.
123. Sieff C., Bicknell D., Caine G., Robinson J., Lan G., Greaves M.F.: Changes in cell surface antigen expression during hemopoietic differentiation. Blood, 60: 703-713, 1982.
124. Sniecinski I.J., Oien L., Petz L.D., Blume G.: Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation, 45: 530-534, 1988.
125. Spivak J.L. (Guest ed.): Erythropoietin: basic and clinical aspects. Hematol./Oncol. Clin. North. Amer., 8: 863-1043, 1994.
126. Spivak J.L., Pham T, Isaacs M., Hawkins D.: Erythropoietin is both a mitogen and a survival factor. Blood, 77: 1228, 1991.
127. Spivak J.L.: Recombinant human erythropoietin and the anemia of cancer. Blood, 84: 997-1004, 1994.
128. Stasi R., Brunetti M., Bussa S., Conforti M., Di Giulio C., Crescenzi A., Terzoli E., Vecchione A., Pagano A.: Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin. Cancer Res., 3: 733-739, 1997.
129. Stebler C., Tichelli A., Dazzi H., Gratwohl A., Nissen C., Speck B.: High dose recombinant erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp. Hematol., 18: 1204-1208, 1990.
130. Steegmann J.L., Lopez J., Otero M.J., Lamana M.L., de la Camara R., Berberana M., Diaz A., Fernandez-Ranada J.M.: Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant., 10: 541-546, 1992.
131. Stein R.S., Abels R.I., Krantz S.B.: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood, 78: 1652-1657, 1991.
132. Stephenson J.E., Axelrad A.A., McLeod D.L., Sheeve M.M.: Induction of colonies of hemoglobin synthetizing cells by erythropoietin in vitro. Proc. Natl. Acad. Sci. USA, 68: 1542, 1971.
133. Stomatoyannopoulos G., Veith R., Al-Khatti A., Papayannopoulou T.: Induction of fetal hemoglobin by cell-cycle specific drugs and recombinant erythropoietin. Am. J. Pediat. Hematol./Oncol., 12: 21, 1990.
134. Takahashi M., Takeda J., Hirose S., Hyman R., Inove N., Miyata T., Ueda E., Kitani T., Medof M.E., Kinoshita T.: Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosil phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med., 177: 517-523, 1993.
135. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T.: Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell, 73: 703-711, 1993.
136. Taniguchi S., Yamasaki K., Shibuya T., Asayama R., Harada M., Niho Y.: Recombinant human erythropoietin for long-term persistent anemia after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant 12: 423-425, 1993.
137. Terstappen L.W., Nguyen M., Huang S., Lazarus H.M., Medof M.E.: Defective and normal hematopoietic stem cells in paroxysmal nocturnal hemoglobinuria. Br. J. Haematol., 84: 504-514, 1993.
138. Tsai P.H., Arkin S., Lipton J.: An intrinsic progenitor defect in Diamond-Blackfan anaemia. Br. J. Hematol., 73: 112, 1989.
139. Vannucchi A.M., Bosi A., Grossi A., Guidi S., Saccardi R., Rossi-Ferrini P.: Down-modulation of serum erythopoietin levels following cyclosporin A infusion. Bone Marrow Transplant., 13: 497-498, 1994.
140. Vannucchi A.M., Bosi A., Grossi A., Rossi Ferrini R.L.: The role of erythropoietin in bone marrow transplantation. Forum, 3: 42-50, 1993.
141. Vannucchi A.M., Grossi A., Bosi A., Rafanelli D., Statello M., Guidi S., Saccardi R., Rossi-Ferrini P.: Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood, 82: 978-984, 1993.
142. Vannucchi A.M., Grossi A., Rafanelli D., Statello M., Cinotti S., Rossi-Ferrini P.: Inhibition of erythropoietin production in vitro by human interferon gamma. Br. J. Haematol., 87: 18-23, 1994.
143. Volin L., Ruutu T.: Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation. Acta Haematol., 84: 195-197, 1990.
144. Whitcomb W.H., Peschle C., Moore C., Nitschke R., Adamson W.: Congenital erythrocytosis: a new form associated with an erythropoietin-dependent mechanism. Br. J. Hematol., 44: 17-24, 1980.
145. Zanjani E.D., Ascensao J.L., McGlave R.B., Banisadre M., Ash R.C.: Studies on the liver to kidney switch of erythropoietin production. J. Clin. Invest., 1981; 67: 1183.
146. Zanjani E.D., Lutton J.D., Huffman R., Wasserman R.: Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J. Clin. Invest., 59: 841, 1977.